An H5N1 vaccination effort will be hampered in a few ways, relating to NIH, FDA, CDC, and HHS leads being baseline anti-vax:

1. NIH co-development/funding for H5N1 vaccine development will be slow.
2. FDA EUA will be slow HHS and CDC leads will probably emphasize vax risk, lower uptake.

(3/11)